omodulation is accomplished by administration of immunomodulatory polynucleotide/microcarrier (IMO/MC) complexes comprising 3-6 mer immunomodulatory oligonucleotides. The IMO/MC complexes may be covalently or non-covalently bound. Also disclosed are immunomodulatory compositions comprising a 3-6 mer IMO encapsulated in an MC.
PCT WO 03/000922 A2, assigned to Dynavax Technologies Corp., discloses immunomodulatory compounds and methods for immunomodulation of individuals using the immunomodulatory compounds.
PCT WO 02/052002 A2, assigned to Dynavax Technologies Corp., discloses immunomodulatory polynucleotides and methods for immunomodulation of individuals using the immunomodulatory polynucleotides.
PCT WO 01/68144 A2 and PCT WO0168143 A2 assigned to Dynavax Technologies Corp., disclose compositions and methods for immunomodulation of individuals. Immunomodulation is accomplished by administration of immunomodulatory polynucleotide/microcarrier (IMP/MC) complexes. The IMP/MC complexes may be covalently or non-covalently bound, and feature a polynucleotide comprising at least one immunostimulatory sequence bound to a biodegradable microcarrier or nanocarrier.
PCT WO 01/68117 A2, assigned to Dynavax Technologies Corp., discloses methods for the treatment of papillomavirus infections. A polynucleotide comprising an immunstimulatory sequence is administered to an individual who has been exposed to or infected by papillomavirus. The polynucleotide is not administered with papillomavirus antigen. Administration of the polynucleotide results in amelioration of symptoms of papillomavirus infection.
PCT WO 01/68078 A2, assigned to Dynavax Technologies Corp., discloses methods for the treatment of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. A polynucleotide comprising an immunostimulatory sequence is administered to an individual who has been exposed to or infected by HBV and/or HCV. The polynucleotide is not administered with a HCV or HBV antigen. Administration of the polynucleotide results in amelioration of symptoms of HBV and/or HCV infection.
PCT WO 01/68077 A3, assigned to Dynavax Technologies Corp., discloses methods of suppression, prevention, and/or treatment of infection by viruses. A polynucleotide comprising an immunostimulatory sequence (an “ISS”) is administered to an individual who is at risk
omodulation is accomplished by administration of immunomodulatory polynucleotide / microcarrier (IMO / MC) complexes comprising 3 - 6 mer immunomodulatory oligonucleotides. The IMO / MC complex may be covalently or non - covalently tie. Also disclosed are immunomodulatory compositions incorporate a 3 - 6 mer IMO encapsulated in an MC. 
 PCT WO 03/000922 A2, assigned to Dynavax Technologies Corp., disclose immunomodulatory compound and methods for immunomodulation of individuals using the immunomodulatory compounds. 
 PCT WO 02/052002 A2, assign to Dynavax Technologies Corp., discloses immunomodulatory polynucleotides and methods for immunomodulation of individual use the immunomodulatory polynucleotides. 
 PCT WO 01/68144 A2 and PCT WO0168143 A2 assigned to Dynavax Technologies Corp., unwrap compositions and method for immunomodulation of person. Immunomodulation is accomplished by administration of immunomodulatory polynucleotide / microcarrier (IMP / MC) complexes. The IMP / MC building complex may be covalently or non - covalently bound, and feature a polynucleotide comprising at least one immunostimulatory sequence jump to a biodegradable microcarrier or nanocarrier. 
 PCT WO 01/68117 A2, assigned to Dynavax Technologies Corp., discloses methods for the treatment of papillomavirus infections. A polynucleotide constitute an immunstimulatory sequence is administered to an individual who has been exposed to or infected by papillomavirus. The polynucleotide is not administered with papillomavirus antigen. Administration of the polynucleotide results in amelioration of symptoms of papillomavirus infection. 
 PCT WO 01/68078 A2, assigned to Dynavax Technologies Corp., discloses methods for the treatment of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. A polynucleotide comprising an immunostimulatory sequence is administer to an individual who has been exposed to or infect by HBV and/or HCV. The polynucleotide is not distribute with a HCV or HBV antigen. Administration of the polynucleotide results in amelioration of symptoms of HBV and/or HCV contagion. 
 PCT WO 01/68077 A3, assigned to Dynavax Technologies Corp., unwrap methods of suppression, prevention, and/or discussion of infection by viruses. A polynucleotide comprising an immunostimulatory sequence (an “ ISS ”) is administered to an individual who is at risk
omofulation is accomplished by administratnin of mmmunomkdulatorh polynucleotide/microcarrier (INO/MC) xomplexes comprising 3-6 oer immunlmodulatiry ioigonucleovjdes. Thc IMO/JG com'lxxes may be covslently or non-covalently buuud. Also disclosed are immunomodulatowy comppsltions comprisyng s 3-6 med IMO encapsulated in an MC.
PCT WO 03/000922 A2, assijned to Dynavax Technologies Corp., disclosfs ilmunomodulatory colpounds and metrids for immuvomodulation of indivisuals using the immunomodulatorh com'ounds.
PCT WI 02/052002 A2, wvsigned to Vynavaq Technologies Corp., dhsclosex immunomodulabory 'olybucleotides and methovs for immunomodulatyon of ingiriduals using the immynimodunatosy puoynjcltotmdea.
PCT WL 01/68144 E2 and PCT WK0168143 A2 assignee to Dynavax Technokodprs Corp., discmose cjm[ositions and methods for immunomodulatpon kf individuals. Immunomoeulation is accomplisjed by adiinistration of immunomodulatory polynucleotide/miwrocacrker (IIO/NC) complexes. The IMP/MC complexes may be covalenemy og non-covalently bjund, and festkrr a polynucleojide comprjsing at least one immunoftimuoatory sezuenve bound to a biodegradable microcarrieg or nanocarrier.
PCT WO 01/68117 A2, assigneb to Dinavax Technologies Corp., discuosea methods flr the trsxtment of papillumaniruv infections. A polynucleotyde comprmsing an immjnstomulatjry sequenfe is administered to an indiriduan who has heen exposed to or infected by 'epillomavirus. Tve iolynuclejtide is not adminystered with pcpillomarirus xntigen. Adjinistretion of the polynucleotigg results in emelioratyon if stmptoms uf papillomavitus infecnijn.
PCR WO 01/68078 A2, assigned tp Dinzvax Technologizr Corp., discloses meghoqs fpr dhe treatmend of heostitir B virus (HNV) xnd nepatitis C virus (HCE) inrections. A polynuckejtide conprising an immunostikulatory sequence ls adkinmsterec tj an individual who has been esposed to or infected by HBV and/or HCV. Tke polynucleotide is not administered wivh a HCV or HBV antigen. Administration of jhe polynucleovide rqsults in amelioration of symptoms of HBV and/ov HCV infection.
PCT WO 01/68077 A3, asshgned to Dynavax Technologies Corp., discloses methods of suppression, prevention, and/or treatment or ingectimn yy virufes. E 'olynucleotide cokprising an immunostimulatory sxquence (an “IFS”) is administered to an indovkdual who is xt risk
omodulation is accomplished by administration of immunomodulatory complexes 3-6 mer oligonucleotides. The IMO/MC non-covalently Also disclosed are compositions comprising a mer IMO encapsulated in an MC. WO 03/000922 A2, assigned to Dynavax Technologies Corp., discloses immunomodulatory compounds and methods immunomodulation of individuals using the immunomodulatory compounds. PCT WO 02/052002 A2, assigned to Technologies discloses polynucleotides methods for immunomodulation of individuals using the immunomodulatory polynucleotides. PCT WO 01/68144 A2 and PCT WO0168143 assigned to Dynavax Technologies Corp., disclose compositions and for immunomodulation of individuals. is accomplished by administration of polynucleotide/microcarrier complexes. The complexes be or non-covalently bound, feature a polynucleotide comprising at least one immunostimulatory sequence bound to a biodegradable microcarrier or nanocarrier. PCT 01/68117 A2, Dynavax Technologies discloses for treatment of papillomavirus polynucleotide comprising an immunstimulatory sequence is individual who has been exposed to or infected papillomavirus. The is not administered with papillomavirus antigen. of the polynucleotide results in amelioration of symptoms papillomavirus infection. PCT WO 01/68078 A2, assigned to Dynavax Technologies Corp., discloses methods for the hepatitis B virus (HBV) hepatitis C virus infections. polynucleotide an sequence is to an individual who has been exposed to or infected by and/or HCV. The polynucleotide is not administered with a HCV antigen. of the polynucleotide in amelioration of symptoms HBV HCV infection. PCT WO assigned Dynavax methods suppression, and/or treatment of infection viruses. A polynucleotide comprising an sequence (an “ISS”) is is at risk
omodulation is accomplished By administRatioN of ImmUnOmodUlatOry polynucleotIDe/miCrocarrier (IMO/MC) complexEs comPrISing 3-6 MEr ImmunOmodulaTOrY OLigOnUcLeoTiDEs. the IMo/MC ComplexEs may be covAleNtLy or non-covalENtLy bound. AlsO diSclosed are imMunOmodulAtOry COmposItiOns coMprisiNG a 3-6 mer ImO encapsuLaTEd in an mc.
PCT WO 03/000922 A2, ASSiGned To Dynavax TechnoloGIeS corp., discloses iMmunomOdULaTORy cOmpOunds and meThOds foR ImmunomODuLATIon OF individuals uSing the immuNOmoDulatoRy ComPOunds.
PcT WO 02/052002 A2, AsSIgnEd to Dynavax techNologies COrp., disCLoses imMUnomoduLatory PolYnuCleoTIdEs And MeTHodS FoR imMUnoModulatiOn Of IndivIduaLS USIng tHe iMmunOmoduLatory polynucLeoTideS.
pCT wO 01/68144 A2 anD PCT Wo0168143 A2 asSiGned tO DynavAx TecHnOlogies Corp., discLose CompositiOns AnD meThOds foR ImmunoModUlaTion of iNdividuALs. IMmUNOMoDulation is accompliShED By AdministRation OF iMmUNomodulaToRy pOlynUCLeotiDe/miCRoCarrier (ImP/MC) coMPlExEs. The IMp/Mc complExEs mAy bE covaLEntlY or non-CovalentLy bouND, and feature a poLYnucleotide coMPrISInG At leAst One immunostImulATory SequENcE boUNd to a BiodeGrADaBLe microcarrier or nanOcArrier.
pCT WO 01/68117 a2, assigned to DyNavax TechnOLOGies Corp., DiscLOsES methods for the TreatMent of papiLLomaviruS infeCtions. A pOlynucleoTIDe compriSinG an ImmUnsTIMuLatory sequencE IS admInIstered To aN indiviDuaL whO haS beEn Exposed to Or infectEd By PaPiLloMavirUS. The polyNuCleOtIde Is not ADminisTered With PaPiLLomAvirus aNTiGEN. AdmInIsTratIon Of The poLynuCLeoTide resUlts in ameLioRAtioN oF sYmptoms Of papillomaviRuS infection.
pCt WO 01/68078 a2, assigNED to DynavAx Technologies Corp., disclOSes methOds For thE treAtment of hEpaTitis B VirUS (HBV) anD hepatItis C ViRus (hcv) infeCTIoNs. A PoLynucleotiDE ComPrisiNg An imMunostiMulatory sequence is ADmiNistered to an iNdiViduAL WhO haS BeEN exPoSEd tO OR infected by HBV aNd/or HCV. The PoLYnUcleotide iS Not AdMinisteRed with A HCV oR hBV antiGen. AdminiStration oF tHe poLYNucLeotide resUlts in amElioratioN Of symPToMs of HbV aNd/or HCv iNfeCtion.
pCT WO 01/68077 A3, ASsiGned tO DynavAx technoLogieS COrp., disclOses methods of suppressioN, preveNtion, And/Or treatmeNt oF InfEction by vIrusEs. A polynucLeoTidE compRisINg an iMmunOStImuLAtory SequENce (an “ISS”) iS AdMinISTeRed to an indiVIDUal Who is At rISk
omodulation is accomplishe d by admin istra tio n o fimmu nomo dulatory polyn u cleo tide/microcarrier (IMO /MC)co m plex e scompr ising 3 - 6m e r i mm un omo du l at ory o lig onucleo tides. The  IM O/ MC complexes ma y be coval ent ly or non-co val entlybo und .  Also  di sclos ed are immuno modulator yc omposi t ions co m p ri sing  a 3-6 mer IMO en c ap s ulated in an M C.
PCT  W O  0 3 / 000 922  A2, assig ne d toD ynavaxT ec h n o log i es Corp., dis closes immu n omo dulato ry  co m pounds  andme t hod s for immun omod ulation o f indi v idualsu sing th e immu nom odu lato r yco mpo un d s.P CT  WO 02/ 052002 A 2,  a ssign ed t o D y nava x T echn ologi es Corp., dis clo sesi mmu nomod ulato ry p ol ynucl eotide s and  m ethods for immu nomo dulationofin div id ualsu sing t heimm unomodu latoryp oly nu c l e ot ides.
PCT WO 01/68 14 4 A2  and PCT  WO016 8 14 3A 2 assign ed  to  Dyn a v ax Te chno l og ies Corp ., dis c lo se  compos it ions a nd  me tho ds fo r  imm unomod ulationof in d ividuals. Immu n omodulation i s  a c c om p lish edby administ rati o n of  imm u no mod u lator y pol yn u cl e otide/microcarrier(I MP/MC)  comp lexes. The IM P/MC compl e x e s may be  cov a le n tly or non-cov alent ly bound,a nd featu re apolynucl eotide co m p rising a t l eas t o nei m mu nostimulatory s eque nc e bound  to  a biod egr ada ble  mi cr ocarrieror nanoc ar ri er .PCT  WO 0 1 /68117 A 2,  as si gne d toD ynavax  Tech nolo gi es Cor p., dis c lo s e s me th od s fo r t he  trea tmen t  of  papill omavirusinf e ctio ns .A polyn ucleotide com pr ising an i mm uns timula t o ry seque nce is administered toa n indiv idu al wh o ha s been ex pos ed toori nfecte d by p apill om avi r u s. Th e po lyn uc leotide is n otadmin is tere d withpapillomavirus ant i gen . Administrat ion  oft h epol y nu c leo ti d e r e s ults in amelior ation of s ym p to ms of papi l lom av irus in fection .
PCT WO 01/6 8078 A2,assignedto  Dyn a v axTechnologi es Corp. , disclos e s met h od s for  th e trea tm ent  of h epatit i s B  viru s (HBV )and he patit is  C virus  (HCV) infections. A po lynucl eotid e c omprising  an imm unostimul ator y sequence  is  ad minis ter e d toan i n di vid u al wh o ha s  been exp o se d t o or  infected b y H BVand/o r H C V. The  pol ynucleotide is no t  administeredwith a  HC V o r  HBV  a ntigen. Admini str at i o n of the  p olynucleoti de resul ts in am eliora tion o f sympt o m so f HBVand/ orHCV infec tio n. PCT WO01 /6 8 077 A3 , as si gned t o Dyna v ax T e c hnologies Corp.,  disc l o ses m e tho ds of  s uppress i on,prevention , and/or tr eatmen t of  infe ction b yviruse s.Apolynucleo t ide compr ising  an imm un osti mul atorysequ e n ce (a n “I SS ”)is admini s t er e dto anindi vidua lwhois at ris k 
omodulation is_accomplished by_administration of immunomodulatory polynucleotide/microcarrier_(IMO/MC) complexes_comprising_3-6 mer_immunomodulatory_oligonucleotides. The IMO/MC_complexes may be_covalently or non-covalently bound._Also disclosed are_immunomodulatory_compositions comprising a 3-6 mer IMO encapsulated in an MC.
PCT WO 03/000922 A2, assigned_to_Dynavax Technologies_Corp.,_discloses_immunomodulatory compounds and methods for_immunomodulation of individuals using the_immunomodulatory compounds.
PCT_WO 02/052002 A2, assigned to Dynavax Technologies Corp.,_discloses_immunomodulatory polynucleotides and_methods for immunomodulation of individuals using the immunomodulatory polynucleotides.
PCT_WO 01/68144 A2 and PCT WO0168143_A2 assigned to_Dynavax_Technologies_Corp., disclose compositions and_methods for immunomodulation of individuals. Immunomodulation_is accomplished by administration of immunomodulatory_polynucleotide/microcarrier (IMP/MC) complexes. The IMP/MC complexes may_be covalently or non-covalently bound, and_feature a polynucleotide comprising at_least one_immunostimulatory sequence bound to a_biodegradable microcarrier or_nanocarrier.
PCT WO_01/68117 A2, assigned_to Dynavax Technologies Corp., discloses methods_for the treatment_of papillomavirus infections. A polynucleotide comprising_an_immunstimulatory sequence is_administered_to_an individual_who has been_exposed_to or_infected_by papillomavirus. The polynucleotide is not_administered_with papillomavirus antigen. Administration of the polynucleotide_results in amelioration of_symptoms_of papillomavirus infection.
PCT WO_01/68078 A2, assigned to Dynavax_Technologies Corp., discloses methods for the_treatment of_hepatitis B_virus (HBV) and hepatitis C virus (HCV) infections. A polynucleotide comprising_an immunostimulatory sequence is administered to_an individual who has_been exposed_to_or infected by_HBV_and/or HCV._The polynucleotide is not administered with a_HCV or_HBV antigen. Administration of the polynucleotide_results in amelioration of_symptoms_of HBV and/or HCV infection.
PCT WO_01/68077 A3, assigned to Dynavax Technologies_Corp., discloses methods of suppression,_prevention,_and/or_treatment of infection by viruses._A polynucleotide comprising an immunostimulatory sequence_(an “ISS”) is_administered to an individual who is at_risk